KIF18B and nasopharyngeal carcinoma: Besides, the anti-tumor immunity conferred by CD8+ T cell contributed to tumor regression and improved prognosis in NPC patients (54, 55), which in line with our finding that low KIF18B expression group exhibited better prognosis.